Previous 10 | Next 10 |
Biotech stocks are officially in a slump. After a rip-roaring 2020 fueled by the advent of COVID-19 vaccines and therapeutics, the iShares Nasdaq Biotechnology ETF has now lost 10% of its value in the past three months. The industry has suddenly lost favor with investors because of ...
Shares of Agenus (NASDAQ: AGEN) skyrocketed 20.6% on Tuesday. The big gain came after the company announced a deal to license bispecific antibody program AGEN1777 to Bristol Myers Squibb (NYSE: BMY) . What really lit a fire under the biotech stock from today's news w...
Agenus (AGEN) shares are up 22% in afternoon trading following this morning's announcement that the biotech exclusively licensed its proprietary bispecific antibody program, AGEN1777, to Bristol-Myers Squibb in a deal potentially worth in excess of $1.5B.Agenus is getting ...
Gainers: Onconova Therapeutics (ONTX) +44%.Park City (PCYG) +27%.Agenus (AGEN) +26%.Ultralife (ULBI) +23%.Virios Therapeutics (VIRI) +23%.Lordstown Motors (RIDE) +22%.Aemetis (AMTX) +22%.Aterian (ATER) +21%.Orbital Energy (OEG) +20%.BM Technologies (BMTX) +19%.Losers: Evofem Bioscie...
3 Biotech Penny Stocks to Buy [Or Sell] Today As we approach the end of May, biotech penny stocks are on fire. While there is no one reason for these penny stocks to be seeing sizable gains, we can attribute it to a few potential factors. On one hand, the entire list of penny ...
LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus execu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ever since “meme stock madness” screeched to a halt, small-cap stocks have been in a slump. That’s been especially the case for speculative biotech plays. Earlier this year, speculators on platforms lik...
Shares of Agenus (NASDAQ: AGEN) were tumbling 4.9% lower as of 3:44 p.m. EDT on Thursday after falling as much as 7.5% earlier in the day. The decline came after the company provided its first-quarter update before the market opened. Agenus reported revenue of $11.7 million in t...
Image source: The Motley Fool. Agenus Inc (NASDAQ: AGEN) Q1 2021 Earnings Call May 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus Inc (AGEN) Q1 2021 Earnings Call Transcript
Agenus Inc. (AGEN) Q1 2021 Earnings Conference Call May 06, 2021 8:30 AM ET Company Participants John Medina – Director-Investor Relations Garo Armen – Chairman and Chief Executive Officer Jennifer Buell – President and Chief Operating Officer Steven O'Day – Chief ...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...